NCT00684294

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Mary Crowley Medical Research Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches. However, four primary factors limit the generation of effective immune mediated anticancer activity in therapeutic application: 1. identifying and/or targeting cancer associated immunogen(s) in an individual patient 2. insufficient or inhibited level of antigen presenting cell priming and/or presentation 3. suboptimal T cell activation and proliferation 4. cancer-induced inhibition of the anticancer immune response in both afferent and efferent limbs. In an effort to overcome these limitations, we have designed a novel autologous vaccine to address inability to fully identify cancer associated antigens, antigen recognition by the immune system (i.e. antigen to immunogen), effector potency, and cancer-induced resistance. We have completed clinical investigations using two different gene vaccine approaches to induce enhancement of tumor antigen recognition which have demonstrated therapeutic efficacy. Specifically, both the use of a GMCSF gene transduced vaccine and a TGFβ2 antisense gene vaccine, in separate trials, have demonstrated similar beneficial effects without any evidence of significant toxicity in advanced cancer patients. The GMCSF transgene directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. These agents have never been used in combination but the rationale of integrating enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression is conceptually sound. We will harvest autologous cancer cells from patients with advanced refractory cancer. We have constructed a TGFβ2 antisense / GMCSF expression vector plasmid and have successfully demonstrated preclinical activity of the vector function following transfection by electroporation and irradiation of autologous cancer tissue.

Conditions

• Carcinoma, Advanced Metastatic

Interventions

Type	Name	Description
BIOLOGICAL	TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine	Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.

Timeline

• Start date: 2008-05-27
• Primary completion: 2009-05-01
• Completion: 2019-05-28
• First posted: 2008-05-26
• Last updated: 2020-03-02

Locations

1 site across 1 country: United States